Bayer's Exposure to Thousands of Cancer Lawsuits Persists as Victims' Lawyers Vow to Continue the Fight
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Amazon.com warehouse workers vote to reject forming union in Alabama
Dallas law firm representing more than 4,000 vows to continue fight for those sickened by Roundup herbicide
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
DALLAS, Feb. 24, 2021 /PRNewswire/ -- Bayer, the maker of Roundup weedkiller, had hoped a proposed multibillion-dollar partial settlement with cancer victims would end its massive legal exposure to pending claims over the herbicide. However, efforts by Bayer (OTC: BAYRY) to resolve lawsuits for pennies on the dollar mean one thing — thousands of cancer victims and their lawyers will continue to press forward to trial seeking justice.
Rather than pursue a comprehensive resolution framework that would have addressed all pending lawsuits, Bayer's strategy has been to negotiate separately with hundreds of law firms.
Trial lawyers opposed to the deal say that is an attempt to reduce liability and cost exposure and kick the can down the road, all for the sake of pleasing shareholders. In addition, courthouse delays caused by the pandemic have put additional pressure on cancer victims to agree to less-than-favorable resolutions. The settlement strategy also muddies the waters regarding the company's liability to future lawsuits.
According to published reports, law firms that were appointed to leadership in the federal multidistrict litigation already reached separate agreements that were higher and materially disproportionate to settlement offers for thousands of lawsuits that are still pending.
"Bayer is trying to turn its back on thousands who became gravely ill after being exposed to Roundup," said Dallas attorney Majed Nachawati of the Fears Nachawati Law Firm, which represents more than 4,000 individual plaintiffs with cases filed almost exclusively in state courts. "We will not let that happen, as a coalition of law firms will continue to press forward to trial."
Roundup's active ingredient, glyphosate, has been linked in published reports to the development of non-Hodgkin's lymphoma and other forms of cancer. Before announcing the proposed partial settlement, juries in three separate trials heard the evidence and returned multimillion-dollar verdicts against Bayer, which acquired the ownership rights to Roundup in 2018.
Trial lawyers opposed to the settlement have also voiced criticism of a related lawsuit filed by class-action lawyer Elizabeth Cabraser because going forward, it would limit the rights of personal injury victims to pursue damages based on their individual injury claims. Bayer continues to sell Roundup, and individuals who are exposed to the product in the future and then fall ill should be allowed to pursue legal action.
"Bayer's lawyers have seen what happens when juries hear this evidence. They think they can get away with this treatment because the pandemic has delayed the ability for cancer victims to go to trial," Mr. Nachawati said. "We will not let that happen without a fight—plain and simple. We will continue to oppose any effort to limit the rights of each individual claimant to get to trial."
Dallas-based Fears | Nachawati Law Firm represents individuals in mass tort litigation, businesses and governmental entities in contingent litigation, and individual victims in complex personal injury litigation. For the past three years, the law firm was ranked number one nationally in product liability filings in federal court. For more information, visit https://www.fnlawfirm.com/.
Media Contact: Robert Tharp 214-458-4007 email@example.com
SOURCE Fears Nachawati Law Firm
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Global Carbon Council receives approval under ICAO's CORSIA to help international airlines meet carbon neutral growth targets
- Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models
- Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021